Literature DB >> 321782

A manual method for applying the Hansch approach to drug design.

J G Topliss.   

Abstract

A procedure is described in which an initial small group of compounds is selected, tested, and ordered according to potency. The potency order in the group is then compared to the tabulated potency order calculated for various parameter dependencies relating to hydrophobic, electronic, and steric effects. From this activity pattern analysis the probable operative parameters can be deduced and a new substituent selection made for the synthesis of potentially more potent analogues. Application of the method is illustrated with a series of examples. It differs from a previously described decision tree, single compound stepwise approach in that it involves the batchwise analysis of small groups of compounds, usually the preferred procedure for logistical reasons if the compounds are relatively easy to synthesize.

Mesh:

Substances:

Year:  1977        PMID: 321782     DOI: 10.1021/jm00214a001

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.

Authors:  Kevin J Frankowski; Michael P Hedrick; Palak Gosalia; Kelin Li; Shenghua Shi; David Whipple; Partha Ghosh; Thomas E Prisinzano; Frank J Schoenen; Ying Su; S Vasile; Eduard Sergienko; Wilson Gray; Santosh Hariharan; Loribelle Milan; Susanne Heynen-Genel; Arianna Mangravita-Novo; Michael Vicchiarelli; Layton H Smith; John M Streicher; Marc G Caron; Lawrence S Barak; Laura M Bohn; Thomas D Y Chung; Jeffrey Aubé
Journal:  ACS Chem Neurosci       Date:  2012-01-20       Impact factor: 4.418

2.  Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.

Authors:  Xiangping Qian; Andrew McDonald; Han-Jie Zhou; Nicholas D Adams; Cynthia A Parrish; Kevin J Duffy; Duke M Fitch; Rosanna Tedesco; Luke W Ashcraft; Bing Yao; Hong Jiang; Jennifer K Huang; Melchor V Marin; Carrie E Aroyan; Jianchao Wang; Seyed Ahmed; Joelle L Burgess; Amita M Chaudhari; Carla A Donatelli; Michael G Darcy; Lance H Ridgers; Ken A Newlander; Stanley J Schmidt; Deping Chai; Mariela Colón; Michael N Zimmerman; Latesh Lad; Roman Sakowicz; Stephen Schauer; Lisa Belmont; Ramesh Baliga; Daniel W Pierce; Jeffrey T Finer; Zhengping Wang; Bradley P Morgan; David J Morgans; Kurt R Auger; Chiu-Mei Sung; Jeff D Carson; Lusong Luo; Erin D Hugger; Robert A Copeland; David Sutton; John D Elliott; Jeffrey R Jackson; Kenneth W Wood; Dashyant Dhanak; Gustave Bergnes; Steven D Knight
Journal:  ACS Med Chem Lett       Date:  2010-01-19       Impact factor: 4.345

3.  Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions.

Authors:  Zhaobing Gao; Tangzhi Zhang; Meng Wu; Qiaojie Xiong; Haiyan Sun; Yinan Zhang; Liansuo Zu; Wei Wang; Min Li
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

4.  Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.

Authors:  Timothy M Acker; Alpa Khatri; Katie M Vance; Cathryn Slabber; John Bacsa; James P Snyder; Stephen F Traynelis; Dennis C Liotta
Journal:  J Med Chem       Date:  2013-08-02       Impact factor: 7.446

5.  Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC).

Authors:  Wentian Wang; Lu Zhang; Lorraine Morlock; Noelle S Williams; Jerry W Shay; Jef K De Brabander
Journal:  J Med Chem       Date:  2019-05-09       Impact factor: 7.446

6.  Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors.

Authors:  Derk J Hogenkamp; Thomas A Ford-Hutchinson; Wen-Yen Li; Edward R Whittemore; Ryan F Yoshimura; Minhtam B Tran; Timothy B C Johnstone; Gavin D Bascom; Hannah Rollins; Lena Lu; Kelvin W Gee
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

7.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

Authors:  Ramesh Gujjar; Alka Marwaha; Farah El Mazouni; John White; Karen L White; Sharon Creason; David M Shackleford; Jeffrey Baldwin; William N Charman; Frederick S Buckner; Susan Charman; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

Review 8.  1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets.

Authors:  U Das; R K Sharma; J R Dimmock
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

9.  Peptoids: a modular approach to drug discovery.

Authors:  R J Simon; R S Kania; R N Zuckermann; V D Huebner; D A Jewell; S Banville; S Ng; L Wang; S Rosenberg; C K Marlowe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Synthesis, in vitro and in vivo cytotoxicity of 6,7-diaryl-2,3,8,8a-tetrahydroindolizin-5(1H)-ones.

Authors:  F Scott Kimball; Ashok Rao Tunoori; Samuel F Victory; Dinah Dutta; Jonathan M White; Richard H Himes; Gunda I Georg
Journal:  Bioorg Med Chem Lett       Date:  2007-06-13       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.